Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.39 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.36 |
| ▸ | CDK7 | P50613 | 4/20 | 0.36 |
| ▸ | CCNH | P51946 | 4/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.36 |
| ▸ | CCNK | O75909 | 3/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190979 | 0.89 | MAPK8 (0.38) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22200734 | 0.88 | EGFR (0.37) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL29357659 | 0.88 | EGFR (0.37) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22190697 | 0.86 | MAPK8 (0.45) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL29354891 | 0.86 | HDAC3 (0.38) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22200720 | 0.86 | HDAC3 (0.38) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22190873 | 0.83 | ERN1 (0.47) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22191004 | 0.83 | ERN1 (0.44) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22190871 | 0.81 | ERN1 (0.50) | MAPK8MAPK10MAPK9ERN1CDK2 | |
| SCHEMBL22191118 | 0.79 | MAPK8 (0.52) | MAPK8MAPK10MAPK9ERN1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | MAPK8 925/4885MAPK10 3731/4885MAPK9 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.